COVID-19, Yellow Fever
Conditions
Keywords
COVID-19, Galidesivir, Yellow Fever
Brief summary
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics, safety and antiviral activity of galidesivir in subjects with yellow fever (YF) or COVID-19.
Detailed description
This is a randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics (PK), safety, and antiviral effects of galidesivir administered via intravenous (IV) infusion vs. placebo in hospitalized adult subjects with either Yellow Fever (Group A) or COVID-19 (Group B). The study will be conducted in two parts, and each Group (A or B) will proceed independently through the study. Part 1 is a dose ranging study with three sequential cohorts of eight patients each that will be randomized 3:1 to receive IV galidesivir or placebo every 12 hours for 7 days. Upon completion of part 1, an optimized dosing regimen of galidesivir will be selected for part 2, based on part 1 results including safety, PK, viral load reduction, and improvement in signs and symptoms and clinical manifestations, and mortality. In part 2, up to 42 patients will be randomized 2:1 to receive IV galidesivir or placebo. After treatment, the patients will remain hospitalized until resolution of symptoms allows release. All patients will be followed for mortality through Day 56.
Interventions
DRUGGalidesivir
Galidesivir IV infusion
DRUGPlacebo
Placebo IV infusion
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID)
BioCryst Pharmaceuticals
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Group A - Yellow Fever * Ability to provide written informed consent * Males and nonpregnant, non-breast-feeding females, aged 18 years or older * Subject weight ≥ 50 kg (110 lb.) * Positive test for YFV by molecular amplification of the virus in the blood * First onset of symptoms of YF occurring within the previous 7 days * Male and female subjects must agree to the contraception requirements and must meet the inclusion criteria regarding contraception as outlined in the protocol * CLCR of at least 60 mL/min by Cockcroft-Gault equation * AST \< 5000 u/L * Indirect bilirubin \< 1.5 mg/dL * Neutrophil count \< 7500 /mm3 * International Normalized Ratio (INR) \< 1.5
Exclusion criteria
Group A - Yellow Fever * Any clinically significant medical condition or medical history that, in the opinion of the investigator or sponsor, would interfere with the subject's ability to participate in the study or increase the risk of participation for that subject * Employment by the study site, or an immediate family relationship to either study site employees or Sponsor employee * Lack of suitable veins for venipuncture/cannulation as assessed by the Investigator at Screening * Participation in any other investigational drug or vaccine study currently or within the past 30 days * Diagnosis of YF vaccine-related viscerotropic disease * Subjects with hepatic encephalopathy as defined by Conn Score ≥ 1. * Subject has severe immunosuppression or immunodeficiency, leukemia, lymphoma, thymic disease, generalized malignancy, or radiation therapy (within the past 3 months), or is undergoing current treatment with immunosuppressive drugs, defined as drugs that impair immune responses to infections * A treatment plan for YF that would include concomitant administration of antiviral medications Inclusion Criteria Group B - COVID-19 * Ability to provide written informed consent, accept randomization to any assigned treatment arm, and comply with planned study procedures * Males and nonpregnant, non-breast-feeding females, aged 18 years or older * Male and female subjects must agree to the contraception requirements and must meet the inclusion criteria regarding contraception as outlined in the protocol * Subject weight ≥ 50 kg (110 lb.) * Clinical syndrome consistent with moderate-severe (but not critically ill) COVID-19, defined by at least one of the following: 1. Symptoms of acute viral lower respiratory tract infection, such as fever, non-productive cough, dyspnea, and either 1) a pulse oximetry oxygen saturation (SpO2) ≤ 94% or a respiratory rate \> 24 breaths/minute as measured at rest without use of supplemental oxygen or 2) a clinical requirement for supplemental oxygen treatment or non-invasive mechanical ventilation 2. Radiographic pulmonary findings seen on chest imaging (chest X-ray or computed tomography \[CT scan\]) consistent with COVID-19 * Positive test for SARS-CoV-2 by molecular amplification of the virus in a respiratory specimen (nasopharyngeal, oropharyngeal, lower respiratory tract \[eg, expectorated sputum\]) collected \< 96 hours prior to randomization. Note: subjects may have a positive test recorded prior to screening if they are admitted to the hospital with a presumed case of COVID-19
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| number of subjects with treatment emergent adverse events and serious adverse events | absolute number through the end of the study, approximately 56 days |
| number of subjects with change in laboratory parameters | absolute number and change from baseline through the end of the study, approximately 56 days |
| exposure of galidesivir as measured by plasma concentrations | 24 hours post dose on Day 1 through 12 hours post dose on Day 7 |
Secondary
| Measure | Time frame |
|---|---|
| changes from baseline and time to improvement using NEWS in COVID-19 (Group B) | through Day21 |
| yellow fever virus (YFV) titer (Group A) | change in YFV titer from baseline through Day 21 |
| mortality | mortality at Day 56 |
| antiviral effect on SARS-CoV-2 in the respiratory tract - COVID-19 (Group B) | change in SARS-CoV-2 from baseline through Day 21 |
| changes in clinical status using 8-point ordinal scale in COVID-19 (Group B) | through Day 21 |
Countries
Brazil
Outcome results
None listed